SuperworthAbeona Therapeutics EPS ABEO
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$1.12
- Latest quarter, Q2 FY26
- −$0.35
- −120% on a year earlier
- Fiscal year 2025
- $1.00
Abeona Therapeutics' earnings per share was −$1.12 over the twelve months to Jun 30, 2026, down 272% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.35, down 120% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.00 | n/a |
| FY2024 | −$2.24 | n/a |
| FY2023 | −$2.59 | n/a |
| FY2022 | n/a | n/a |
| FY2021 | −$21.15 | n/a |
| FY2020 | −$22.75 | n/a |
| FY2019 | −$38.25 | n/a |
| FY2018 | −$29.50 | n/a |
| FY2017 | −$16.50 | n/a |
| FY2016 | −$15.75 | n/a |
| FY2015 | −$13.00 | −119% |
| FY2013 | $69.25 | n/a |
| FY2012 | −$650.00 | n/a |
| FY2011 | −$275.00 | n/a |
| FY2010 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.35 | −120% | −$1.12 | |
| Q1 FY26 | −$0.30 | n/a | $0.94 | |
| Q4 FY25 | −$0.37 | n/a | $1.00 | |
| Q3 FY25 | −$0.10 | n/a | $1.18 | |
| Q2 FY25 | $1.71 | n/a | $0.65 | |
| Q1 FY25 | −$0.24 | n/a | −$1.32 | |
| Q4 FY24 | −$0.19 | n/a | −$2.24 | |
| Q3 FY24 | −$0.63 | n/a | −$2.70 | |
| Q2 FY24 | −$0.26 | n/a | −$2.55 | |
| Q1 FY24 | −$1.16 | n/a | −$3.21 | |
| Q4 FY23 | −$0.65 | n/a | −$2.59 | |
| Q3 FY23 | −$0.48 | n/a | −$2.47 |
Against its peers
Companies in Drug Manufacturers - General nearest Abeona Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ABEOAbeona Therapeutics | −$1.12 | −272% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.78 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Abeona Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.